Phase IV Study of DCE-MRI Using Dotarem in Evaluation of Therapeutic Response to Sorafenib in Patients With Advanced Stage HCC.

Trial Profile

Phase IV Study of DCE-MRI Using Dotarem in Evaluation of Therapeutic Response to Sorafenib in Patients With Advanced Stage HCC.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Gadoterate-meglumine (Primary)
  • Indications Liver cancer
  • Focus Diagnostic use
  • Acronyms DCE-MRI
  • Sponsors Guerbet
  • Most Recent Events

    • 23 Feb 2017 Planned End Date changed from 1 Dec 2016 to 1 Oct 2017.
    • 19 Aug 2016 Planned End Date changed from 1 Jun 2016 to 1 Dec 2016.
    • 11 Feb 2016 Planned End Date changed from 1 Aug 2015 to 1 Jun 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top